Inclusion Criteria:

- Patients must have metastatic or recurrent squamous cell carcinoma of the
esophagus.

- Patients must have histologically or cytologically confirmed disease.

- Patients may have received one prior regimen of neoadjuvant chemotherapy or
chemoradiation, and prior esophagectomy is acceptable. Patients may also have
received one prior chemotherapy regimen for recurrent disease.

- Patients may have received no more than 4500 cGy to fields including substantial
marrow.

- Age greater than or equal than 18 years. Because no dosing or adverse event data are
currently available on the use of GW572016 in patients <18 years of age, children are
excluded from this study.

- Life expectancy of greater than 12 weeks.

- Patients must have normal organ and marrow function as defined below:

Leukocytes greater than or equal to 3,000/microliters Absolute neutrophil count greater
than or equal to 1,500/microliters Platelets greater than or equal to 100,000/microliters
Total bilirubin within normal institutional limits AST(SGOT)/ALT(SGPT)less than or equal
to 2.5 X institutional upper limit of normal Creatine within normal institutional limits
OR creatinine clearance greater than or equal to 60 ml/min for patients with creatinine
levels above institutional normal

-Cardiac ejection fraction within the institutional range of normal as measured by
echocardiogram or MUGA scan. A normal ejection fraction is equal or greater than 50%.
Baseline and on treatment scans should be performed using the same modality and preferably
at the same institution.